Rosa Pasqualina De Vincenzo

Medicine & Life Sciences

1. Breast Neoplasms 12%
2. Budgets 11%
3. Cervical Intraepithelial Neoplasia 26%
4. Cervix Uteri 11%
5. Cold Temperature 11%
6. Colposcopy 19%
7. Conization 100%
8. Cost-Benefit Analysis 10%
9. Cross Protection 13%
10. Drug Therapy 23%
11. Economics 11%
12. Endometrial Neoplasms 19%
13. Epirubicin 12%
14. Fertility 10%
15. Fetus 15%
16. Hysterectomy 32%
17. Italy 17%
18. Laryngeal Neoplasms 11%
19. Life Expectancy 9%
20. liposomal doxorubicin 18%
21. Longitudinal Studies 16%
22. Neoadjuvant Therapy 14%
23. Neoplasms 10%
24. Nomograms 11%
25. Observational Studies 18%
26. Oncologists 10%
27. Ovarian Neoplasms 35%
28. Papillomavirus Infections 11%
29. Papillomavirus Vaccines 18%
30. Pathology 11%
31. Pelvic Neoplasms 14%
32. Platinum 17%
33. Pregnancy 29%
34. Propensity Score 34%
35. Prospective Studies 19%
36. Psychological Distress 19%
37. Quality of Life 18%
38. Quality-Adjusted Life Years 10%
39. Recurrence 17%
40. Response Evaluation Criteria in Solid Tumors 14%
41. tetraethylpyrazine 15%
42. Therapeutics 13%
43. TP protocol 15%
44. Trabectedin 46%
45. tumor necrosis factor-alpha, CNGRC fusion protein, human 20%
46. Uterine Cervical Dysplasia 32%
47. Uterine Cervical Neoplasms 80%
48. Vaccination 38%
49. varespladib methyl 20%
50. Vulva 12%